Verapamil Hydrochloride Tablet
NDC Package 23155-059-01

EA - Billing unit of "each" is used when the product is dispensed in discreet units.

100 EA

Verapamil Hydrochloride

Verapamil Hydrochloride

Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.

Oral - Administration to or by way of the mouth.

Verapamil hydrochloride tablets USP are indicated for the treatment of the following:Angina 1.Angina at rest including:     -Vasospastic (Prinzmetal's variant) angina     -Unstable (crescendo, pre-infarction) angina 2.Chronic stable angina (classic effort-associated angina)Arrhythmias 1.In association with digitalis for the control of ventricular rate at rest and during stress in patients with chronic atrial flutter and/or atrial fibrillation (see WARNINGS: Accessory bypass tract ) 2.Prophylaxis of repetitive paroxysmal supraventricular tachycardiaEssential hypertension Verapamil hydrochloride is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

Heritage Pharmaceuticals Inc. D/b/a Avet Pharmaceuticals Inc.

Human Prescription Drug

ANDA071881

ANDA - A product marketed under an approved Abbreviated New Drug Application.

10-15-2015

12-31-2026

N

No